The 20th International Congress on In Vitro Toxicology (ESTIV2018) is coming and it will be a great occasion for HCS-Pharma to showcase our current co-development, with the institute du thorax of Nantes and the RHU CHOPIN, on the use of hepatocyte-like cells differentiated from human induced pluripotent stem cells (hiPSC) into BIOMIMESYS® to study metabolic diseases.

Méryl Roudaut will have the privilege to give a presentation on Monday, October 15th in Session 1 – Bio-engineering and stem cell models entitled: Development and automation of 3D innovative hiPSC-based models including the microenvironment for phenotypic screening – Application on metabolic diseases.

We hope to see you there and to discuss on this topic with you! If you want to book a meeting, please let us known.


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.